CD47 and acute myeloid leukemia: Clinical studies confirmed the importance of inhibiting CD47/SIRP-α interaction and several CD47/SIRP-α mAbs or fusion proteins are currently in phase I/II, as a single or combination therapy for adult AML (NCT05266274, NCT04980885, NCT02641002, NCT02678338, NCT04755244, NCT05263271, NCT05607199, NCT05367401, NCT04214249).